Phase 2 Lung Cancer Trial, Recruiting NCT03290534 Sponsor: CivaTech Oncology Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT03290534
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their signed informed consent to participate
  • People with suspected or confirmed non-small cell lung cancer (a common type of lung cancer) located in the upper part of either lung
  • People who have a lung nodule (a small growth in the lung) that is suspected to be non-small cell lung cancer
  • People whose lung mass measures 7 cm or smaller at its widest point, as measured by a CT scan of the chest and upper abdomen
  • People whose cancer is at an early stage, classified as clinical stage I or stage II (meaning it has not spread far)
  • People who are not currently pregnant or breastfeeding
  • Women who have not yet gone through menopause and have had a negative pregnancy test
  • People who are able to have children and are using effective contraception
  • People who had a previous cancer more than 5 years ago, as long as that cancer was not a type of skin cancer (non-melanoma) or a very early-stage cancer that had not spread (in-situ cancer)

Who may not be able to join:

  • No specific exclusion criteria were listed in the official trial documentation (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
CivaTech Oncology
Registry
ClinicalTrials.gov
Start date
13 March 2019
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Local Control Rate at 1 year

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov